Background
RaiLee Mar was born 12 weeks prematurely, placing her at high risk for necrotizing enterocolitis (NEC), a dangerous gastrointestinal disease. Initially fed her mother’s milk, her care team switched to Abbott Laboratories’ cow’s-milk-based formula, Similac Special Care 24, after her mother, Ericka Mar, could no longer produce usable milk and the hospital had no donor milk available. One day after starting the formula, RaiLee was diagnosed with NEC and died the next day.
Ericka Mar sued Abbott, alleging that the company failed to adequately warn of the risks of NEC associated with its formula. Her suit was selected as a bellwether case in a large multi-district litigation. The packaging for the formula included the warning, “USE AS DIRECTED BY A DOCTOR.” Mar argued that a more specific warning about the increased risk of NEC compared to human milk would have prevented RaiLee’s death.
The U.S. District Court for the Northern District of Illinois granted summary judgment to Abbott. It concluded that Mar had failed to produce sufficient evidence that her proposed alternative warning would have changed the outcome, as the formula was the only available food source for the infant at the time. Mar appealed the decision.
The Court’s Holding
The Seventh Circuit affirmed the district court’s grant of summary judgment, holding that Mar had not shown that a different warning would have prevented her daughter’s death. Under the governing West Virginia law, a plaintiff in a failure-to-warn case must prove that the manufacturer’s failure to warn was the cause-in-fact of the injury—in other words, that an adequate warning would have “made a difference.” The court found Mar’s arguments that a different warning would have changed the outcome to be too speculative to proceed to a jury.
The court rejected Mar’s three primary counterfactual arguments. First, it was unreasonable to infer that her proposed warning would have spurred the hospital to establish a donor-milk program in time to help RaiLee, given the treating physician’s testimony about the immense cost, time, and logistical hurdles involved. Second, the court found it was mere conjecture to suggest the hospital would have violated its own safety policy by using unpasteurized milk from another patient. Third, Mar’s claim that she would have acted differently was defeated by the fact that she had not read the existing warning label, a prerequisite for such claims under West Virginia law.
The court concluded that while the case was tragic, the inferences Mar asked the court to draw were not sufficiently grounded in evidence and were “supported only by speculation.” The court also affirmed the denial of Mar’s motion to reconsider, as the “new” evidence she sought to introduce was available to her during the initial proceedings.
Key Takeaways
- To succeed on a failure-to-warn claim, a plaintiff must prove causation by showing that an alternative, adequate warning would have actually altered the outcome and prevented the injury.
- Courts will not permit a case to go to a jury based on a “string of inferences” or speculation about what might have happened in a hypothetical scenario.
- A plaintiff’s failure to read the original product warning can be fatal to a failure-to-warn claim in jurisdictions that require it.
- The practical realities and constraints of a situation, such as the lack of medical alternatives, can be a deciding factor in determining whether a different warning would have made a difference.
Why It Matters
This decision reinforces the significant burden on plaintiffs to prove causation in products liability cases based on a failure-to-warn theory. It clarifies that merely pointing to a theoretical alternative course of action is insufficient; there must be concrete evidence to suggest that the alternative was plausible and that the defendant’s warning was the decisive factor in it not being pursued. For manufacturers, the ruling demonstrates that when their products are used in high-stakes medical situations where no other options are available, courts may find that a different warning would have been futile, shielding the company from liability.
The ruling is a notable development in the ongoing litigation surrounding NEC and infant formula. It highlights the difficulty of establishing legal causation when a product is administered by medical professionals who are already aware of the general risks involved and are facing a lack of better alternatives. The court’s focus on the practical, on-the-ground realities faced by the hospital underscores the challenges of bringing these complex cases.